お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、注意欠陥多動性障害(ADHD)治療薬の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に注意欠陥多動性障害(ADHD)治療薬市場を分類しています。
本レポートでは世界の注意欠陥多動性障害(ADHD)治療薬市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Eli Lilly and Company、Novartis、Takeda、Pfizer、GlaxoSmithKline、Mallinckrodt Pharmaceuticals、Hisamitsu Pharmaceutical、Impax Laboratories、Johnson ＆Johnson、UCB、Purdue Parma

レポートは注意欠陥多動性障害(ADHD)治療薬の主要生産者を調査し、主要地域や国の消費状況も提供します。注意欠陥多動性障害(ADHD)治療薬の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Stimulants
    Non-Stimulants

用途別の市場セグメント：
    Specialty Clinics
    Hospital Pharmacies
    Retail Pharmacies
    E-Commerce

本レポートの詳細内容
本レポートは、世界の注意欠陥多動性障害(ADHD)治療薬市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて注意欠陥多動性障害(ADHD)治療薬市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）の注意欠陥多動性障害(ADHD)治療薬生産量、成長率、市場シェアを調査している。

二. 消費面では、注意欠陥多動性障害(ADHD)治療薬の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーの注意欠陥多動性障害(ADHD)治療薬売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界の注意欠陥多動性障害(ADHD)治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本注意欠陥多動性障害(ADHD)治療薬のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：注意欠陥多動性障害(ADHD)治療薬のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： 注意欠陥多動性障害(ADHD)治療薬の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおける注意欠陥多動性障害(ADHD)治療薬の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章注意欠陥多動性障害(ADHD)治療薬メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：注意欠陥多動性障害(ADHD)治療薬の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：注意欠陥多動性障害(ADHD)治療薬の主要メーカーの概要を提供し、製品の説明と仕様、注意欠陥多動性障害(ADHD)治療薬の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：注意欠陥多動性障害(ADHD)治療薬の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

ADHD is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.
Market Analysis and Insights: Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
The global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Eli Lilly and Company, Novartis, Takeda, Pfizer, GlaxoSmithKline, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical, Impax Laboratories and Johnson ＆Johnson, etc.

Market Segmentation
By Company
    Eli Lilly and Company
    Novartis
    Takeda
    Pfizer
    GlaxoSmithKline
    Mallinckrodt Pharmaceuticals
    Hisamitsu Pharmaceutical
    Impax Laboratories
    Johnson ＆Johnson
    UCB
    Purdue Parma

Segment by Type
    Stimulants
    Non-Stimulants

Segment by Application
    Specialty Clinics
    Hospital Pharmacies
    Retail Pharmacies
    E-Commerce

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Stimulants
    Table 3. Key Players of Non-Stimulants
    Table 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 5. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2019-2024)
    Table 8. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2025-2030)
    Table 10. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends
    Table 11. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
    Table 12. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
    Table 13. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
    Table 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Players (2019-2024)
    Table 16. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2023)
    Table 17. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 18. Global 5 Largest Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics, Headquarters and Area Served
    Table 20. Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics, Product and Application
    Table 21. Global Key Players of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics, Product and Application
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2019-2024)
    Table 25. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2025-2030)
    Table 27. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Application (2019-2024)
    Table 29. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Share by Application (2025-2030)
    Table 31. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 32. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 33. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 34. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 35. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 37. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 39. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 40. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 41. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 42. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 45. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 46. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 47. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 48. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 49. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 50. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 51. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 52. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 54. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 55. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 56. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 61. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 63. Eli Lilly and Company Company Details
    Table 64. Eli Lilly and Company Business Overview
    Table 65. Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 66. Eli Lilly and Company Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 67. Eli Lilly and Company Recent Developments
    Table 68. Novartis Company Details
    Table 69. Novartis Business Overview
    Table 70. Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 71. Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 72. Novartis Recent Developments
    Table 73. Takeda Company Details
    Table 74. Takeda Business Overview
    Table 75. Takeda Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 76. Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 77. Takeda Recent Developments
    Table 78. Pfizer Company Details
    Table 79. Pfizer Business Overview
    Table 80. Pfizer Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 81. Pfizer Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 82. Pfizer Recent Developments
    Table 83. GlaxoSmithKline Company Details
    Table 84. GlaxoSmithKline Business Overview
    Table 85. GlaxoSmithKline Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 86. GlaxoSmithKline Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 87. GlaxoSmithKline Recent Developments
    Table 88. Mallinckrodt Pharmaceuticals Company Details
    Table 89. Mallinckrodt Pharmaceuticals Business Overview
    Table 90. Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 91. Mallinckrodt Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 92. Mallinckrodt Pharmaceuticals Recent Developments
    Table 93. Hisamitsu Pharmaceutical Company Details
    Table 94. Hisamitsu Pharmaceutical Business Overview
    Table 95. Hisamitsu Pharmaceutical Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 96. Hisamitsu Pharmaceutical Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 97. Hisamitsu Pharmaceutical Recent Developments
    Table 98. Impax Laboratories Company Details
    Table 99. Impax Laboratories Business Overview
    Table 100. Impax Laboratories Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 101. Impax Laboratories Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 102. Impax Laboratories Recent Developments
    Table 103. Johnson ＆Johnson Company Details
    Table 104. Johnson ＆Johnson Business Overview
    Table 105. Johnson ＆Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 106. Johnson ＆Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 107. Johnson ＆Johnson Recent Developments
    Table 108. UCB Company Details
    Table 109. UCB Business Overview
    Table 110. UCB Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 111. UCB Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 112. UCB Recent Developments
    Table 113. Purdue Parma Company Details
    Table 114. Purdue Parma Business Overview
    Table 115. Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product
    Table 116. Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
    Table 117. Purdue Parma Recent Developments
    Table 118. Research Programs/Design for This Report
    Table 119. Key Data Information from Secondary Sources
    Table 120. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Stimulants Features
    Figure 4. Non-Stimulants Features
    Figure 5. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2023 VS 2030
    Figure 7. Specialty Clinics Case Studies
    Figure 8. Hospital Pharmacies Case Studies
    Figure 9. Retail Pharmacies Case Studies
    Figure 10. E-Commerce Case Studies
    Figure 11. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Report Years Considered
    Figure 12. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region: 2023 VS 2030
    Figure 15. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players in 2023
    Figure 16. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2023
    Figure 18. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2019-2030)
    Figure 20. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2019-2030)
    Figure 21. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
    Figure 22. United States Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 25. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2019-2030)
    Figure 26. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2019-2030)
    Figure 27. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
    Figure 28. Germany Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. France Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. U.K. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Italy Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Russia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Nordic Countries Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 35. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2019-2030)
    Figure 36. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2019-2030)
    Figure 37. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2019-2030)
    Figure 39. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2019-2030)
    Figure 40. Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2019-2030)
    Figure 41. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. China Taiwan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Australia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
    Figure 51. Brazil Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Mexico Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Turkey Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Israel Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. GCC Countries Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Eli Lilly and Company Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 58. Novartis Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 59. Takeda Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 60. Pfizer Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 61. GlaxoSmithKline Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 62. Mallinckrodt Pharmaceuticals Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 63. Hisamitsu Pharmaceutical Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 64. Impax Laboratories Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 65. Johnson ＆Johnson Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 66. UCB Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 67. Purdue Parma Revenue Growth Rate in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed